Fig. 4
From: Glypican 3 as target therapy to prevent cell migration and proliferation in rhabdomyosarcoma
Effects of silencing, SULF-2 inhibitor and drugs on cell proliferation, death, and metabolic activity. (A). Cartoon of the experiment. After cell seeding, two siRNA treatments were performed to obtain a lower value of GPC3, followed by SULF2 inhibitor treatment and DOXO administration. (B). Immunofluorescence. Protein expression in siRNA + SULF2-inhibitor + DOXO treated cells. Scale bar: 75 μm. (C). As can be seen in the graphs, Ki67, and GPC3 decrease in treated cells, while death cells (cleaved Cas3 expression) increase. (D). Metabolic activity under different conditions showed that the viability decreased in DOXO-treated cells, and further in ipafricept-treated cells. (Tukey’s post hoc test; *: p < 0.05; ***: p < 0.001, ****: p < 0.0001). N = 4 experiments. In each experiment 4 replicates per each condition.
